Skip to main content


The Common Fund Systems Biology Data Platform (SysBio) Leveraging the Accelerating Medicines Partnership (AMP) Venture Initiative aims to integrate various data types that will allow researchers to explore the role of a specific gene, molecule, cell, or pathway across tissues involved in different diseases. Through the Accelerating Medicines Partnership (AMP), many NIH Institutes and Centers funded research that generated multifaceted data sets in a variety of chronic diseases distributed across multiple data platforms. The SysBio initiative will create a centralized portal and tools so that researchers can search for data across these platforms, empowering reuse and reanalysis of currently disconnected datasets. SysBio will integrate rich data types including phenotypic, clinical, molecular, and patient reported outcomes data. Using data sets from the AMP programs, researchers can explore hypotheses across different tissues in different diseases and identify shared mechanisms within subsets of patients.  This Venture Initiative will lay the groundwork for a future goal of expanding access and tools to include data from other cohorts outside of the AMP programs.


Explore how you can contribute to the SysBio initiative by viewing the SysBio Research Opportunity Announcement (ROA).

Do you have questions about the SysBio ROA? Join the informational webinar on March 18, 2024 at 3:00 - 4:00 PM ET. Learn more. 

News & Announcements

The SysBio initiative has released a new Research Opportunity Announcement (ROA)

Have questions about the SysBio ROA? SysBio held an informational webinar on March 18. Learn more and view the recording.

On January 25th, the NIH Council of Councils approved the concept of the NIH Common Fund's Venture Program. Find out more by browsing the presentation slides and program description. Or watch the videocast

Sign up for the SysBio listserv to stay up to date on the latest news and announcements.

Have a question? Reach out to us at


This page last reviewed on April 12, 2024